Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study

作者：Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I. Spira, Byoung Chul Cho, Sun Min Lim, Yuichiro Ohe, Adnan Nagrial, Jiunn Liang Tan, V. Wainsztein, Elisa Ramos, Maria Campelo, Hiroaki Akamatsu, Danny Nguyen, Alexis B. Cortot, Alona Zer, Dilek Erdem, Rachel E. Sanborn, Till‐Oliver Emde, Anna Minchom, Bogdan Żurawski, Maria Lurdes Ferreira, James Chih‐Hsin Yang, Melina E. Marmarelis, Julia Schuchard, Jefferson Alves, Debopriya Ghosh, Gregor M. Balaburski, Remy B. Verheijen, Liliana Ribeiro, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Natasha B. Leighl · 发表于：European Journal of Cancer · 年份：2025 · DOI：10.1016/j.ejca.2025.115624 · 被引用次数：6 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Lung Cancer Diagnosis and Treatment

INTRODUCTION: Intravenous anticancer treatments present challenges for patients and healthcare professionals (HCPs), prompting the development of subcutaneous formulations. In the phase 3 PALOMA-3 study, subcutaneous amivantamab demonstrated noninferior pharmacokinetics and response rates versus intravenous amivantamab (both with lazertinib), with substantially faster administration, a 5-fold reduction in infusion-related reactions, reduced venous thromboembolism, and numerically prolonged survival. METHODS: Participants with EGFR-mutated NSCLC and progression on osimertinib and chemotherapy were randomized to subcutaneous (n = 206) or intravenous amivantamab (n = 212), plus lazertinib. Resource utilization and participant-reported treatment satisfaction were evaluated at cycle (C) 1 day (D) 1 and C3D1. RESULTS: Time-in-chair was substantially lower for subcutaneous versus intravenous amivantamab (C1D1: median [range], 23 min or 0.4 h [0-12.0 h] vs 6.5 h [0-24.0 h]; C3D1: 35 min or 0.6 h [0-6.6 h] vs 3.4 h [0.5-9.0 h]), as were HCP time and participant time-in-room. More participants who received subcutaneous versus intravenous amivantamab reported feeling unrestricted (C1D1, 66 % vs 29 %; C3D1, 60 % vs 42 %) or unbothered (C1D1, 69 % vs 30 %; C3D1, 71 % vs 45 %) by administration, and reported gaining time for other activities (C1D1, 36 % vs 7 %; C3D1, 37 % vs 6 %). Few participants who received subcutaneous amivantamab reported moderate-to-very severe injection-site pain (C...